Hepatoprotective and neuroprotective effect of taxifolin on hepatic encephalopathy in rats

Basit Öğe Kaydı
dc.contributor.authorOkkay, Ufuk
dc.contributor.authorOkkay, Irmak Ferah
dc.contributor.authorCicek, Betul
dc.contributor.authorAydin, Ismail Cagri
dc.contributor.authorOzkaraca, Mustafa
dc.date.accessioned2024-10-26T18:09:15Z
dc.date.available2024-10-26T18:09:15Z
dc.date.issued2022
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractThis study was planned to assess the potential protective effects of taxifolin against thioacetamide-induced hepatic encephalopathy and subsequently to portray its behavioural results. The experimental model was induced with three doses of (200 mg/kg i.p.) thioacetamide and taxifolin (50 and 100 mg/kg, p.o.) was administered for fourteen days. Taxifolin effectively attenuated hepatic encephalopathy through decrease in AST, ALT, ALP and LDH concentrations and improvement of hyperammonemia, and increase in antioxidant capacity by decreasing MDA, ROS, and increasing CAT and GSH. In addition, the expressions of NF-kappa B, TNF-alpha, IL-1 beta, caspase-3 and Bax was down-regulated while IL-10 and Bcl-2 expressions were up-regulated with taxifolin treatment. The recovery was confirmed by downregulation of iNOS and 8-OHdG expressions in our immunohistochemical analysis. Taxifolin treatment reduced the disrupting role of thioacetamide as seen by corrected hyperammonemia as well as preservation of astrocyte and hepatocyte structure. Elevated plus maze and locomotor activity tests also proved that taxifolin might repeal the neurobehavioral disabilities. In conclusion, taxifolin has shown hepatoprotective and neuroprotective roles with antioxidant and anti-inflammatory effects, as well as suppressing the excessive release of ammonia, and it eventually reversed neurobehavioral impairments.
dc.description.sponsorshipResearch Fund of the Ataturk University [TSA-2019-7527]
dc.description.sponsorshipThis work was supported by Research Fund of the Ataturk University. (Project Number: TSA-2019-7527).
dc.identifier.doi10.1007/s11011-022-00952-3
dc.identifier.endpage1556
dc.identifier.issn0885-7490
dc.identifier.issn1573-7365
dc.identifier.issue5
dc.identifier.pmid35298730
dc.identifier.scopus2-s2.0-85126471187
dc.identifier.scopusqualityQ2
dc.identifier.startpage1541
dc.identifier.urihttps://doi.org/10.1007/s11011-022-00952-3
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30023
dc.identifier.volume37
dc.identifier.wosWOS:000770222800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer/Plenum Publishers
dc.relation.ispartofMetabolic Brain Disease
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectThioacetamide
dc.subjectTaxifolin
dc.subjectInflammation
dc.subjectApoptosis
dc.subjectOxidative stress
dc.subjectHepatic encephalopathy
dc.titleHepatoprotective and neuroprotective effect of taxifolin on hepatic encephalopathy in rats
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu